Corcept Therapeutics (CORT), which announced it received from the FDA a complete response letter regarding the new drug application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism, is set to resume trading at 8:20 am ET, with quotation scheduled to resume at 8:15 am ET.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT: